Showing results (21-30 of 45) with videos related to
Sort By:
Pageof 5
Eclinicalmedicine|January 27, 2025
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialGabriela Tapia-Calle, Gloria Aguilar, Nathalie Vaissiere, et al.Journal of the Pediatric Infectious Diseases Society|September 28, 2024
Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of AgeJavier Ruiz-Guiñazú, Mathieu Le Gars, Vicky Cárdenas, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2013
Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patientsHans-Jürgen Stellbrink, Keikawus Arastéh, Dirk Schürmann, et al.Vaccine|May 5, 2024
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding studyVicky Cárdenas, Mathieu Le Gars, Carla Truyers, et al.Journal of Clinical Epidemiology|August 14, 2010
Estimating prevalence of diabetes in a Congolese town was feasibleMuel Telo Muyer, Erik Muls, Mala A Mapatano, et al.Vaccines|October 26, 2024
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical TrialVeronica V Rezelj, Fred Paddenburg, Marie Enajite Diegbe, et al.The Lancet. Infectious Diseases|September 16, 2022
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, An Vandebosch, Jerald Sadoff, et al.Vaccine|June 6, 2022
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trialsJerald Sadoff, Mathieu Le Gars, Boerries Brandenburg, et al.Annals of Internal Medicine|February 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus VaccineNadine C Salisch, Kathryn E Stephenson, Kristi Williams, et al.The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.Pageof 5